1. Home
  2. NAMS vs PLMR Comparison

NAMS vs PLMR Comparison

Compare NAMS & PLMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • PLMR
  • Stock Information
  • Founded
  • NAMS 2019
  • PLMR 2013
  • Country
  • NAMS Netherlands
  • PLMR United States
  • Employees
  • NAMS N/A
  • PLMR N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • PLMR Property-Casualty Insurers
  • Sector
  • NAMS Health Care
  • PLMR Finance
  • Exchange
  • NAMS Nasdaq
  • PLMR Nasdaq
  • Market Cap
  • NAMS 2.7B
  • PLMR 2.9B
  • IPO Year
  • NAMS N/A
  • PLMR 2019
  • Fundamental
  • Price
  • NAMS $23.54
  • PLMR $109.87
  • Analyst Decision
  • NAMS Strong Buy
  • PLMR Buy
  • Analyst Count
  • NAMS 7
  • PLMR 7
  • Target Price
  • NAMS $38.17
  • PLMR $115.50
  • AVG Volume (30 Days)
  • NAMS 538.3K
  • PLMR 134.4K
  • Earning Date
  • NAMS 02-06-2025
  • PLMR 02-12-2025
  • Dividend Yield
  • NAMS N/A
  • PLMR N/A
  • EPS Growth
  • NAMS N/A
  • PLMR 49.11
  • EPS
  • NAMS N/A
  • PLMR 4.22
  • Revenue
  • NAMS $33,594,000.00
  • PLMR $503,499,000.00
  • Revenue This Year
  • NAMS $131.53
  • PLMR N/A
  • Revenue Next Year
  • NAMS N/A
  • PLMR $21.18
  • P/E Ratio
  • NAMS N/A
  • PLMR $25.98
  • Revenue Growth
  • NAMS 78.77
  • PLMR 40.19
  • 52 Week Low
  • NAMS $15.19
  • PLMR $57.55
  • 52 Week High
  • NAMS $27.29
  • PLMR $112.90
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 44.28
  • PLMR 59.22
  • Support Level
  • NAMS $23.17
  • PLMR $98.42
  • Resistance Level
  • NAMS $26.71
  • PLMR $111.82
  • Average True Range (ATR)
  • NAMS 0.94
  • PLMR 3.04
  • MACD
  • NAMS -0.40
  • PLMR 0.59
  • Stochastic Oscillator
  • NAMS 23.65
  • PLMR 85.45

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About PLMR Palomar Holdings Inc. Common stock

Palomar Holdings Inc is a United States-based company focused on the provision of specialty property insurance earthquake, wind, and flood insurance products. The company's core focus is on the residential and commercial earthquake markets in earthquake-exposed states such as California, Oregon, Washington, and states with exposure to the New Madrid Seismic Zone. It offers specialty property insurance products in the target markets to both individuals and businesses through multiple channels, including retail agents, program administrators, wholesale brokers, and in partnership with other insurance companies. Its products include Residential Earthquake, Commercial Earthquake, Specialty Homeowners, Inland Marine, Commercial All Risk, Hawaii Hurricane, Residential Flood and others.

Share on Social Networks: